DALLAS, Nov. 12, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring StemCells Inc. (Nasdaq:STEM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on StemCells Inc. (Nasdaq:STEM) should be of particular interest to other biopharmaceutical companies: Advanced Cell Technologies Inc. (OTCBB:ACTC), Geron Corp. (Nasdaq:GERN), Genzyme Corp. (Nasdaq:GENZ) and Life Technologies Corp. (Nasdaq:LIFE).
It is available at: http://www.investorsoup.com/lp/STEM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
StemCells Inc. (Nasdaq:STEM) is a biopharmaceutical company engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems.
Message Board Search for STEM: http://www.boardcentral.com/boards/STEM
In the report, the analyst notes:
"STEM announced earlier this month that it has closed the sale of 10 million shares of common stock and warrants to purchase 4 million shares of common stock, for gross proceeds of $12.5 million. The common stock and warrants were sold in units at a price of $1.25 per unit, with each unit consisting of one share of common stock and a warrant to purchase 0.40 share of common stock at an exercise price of $1.50 per share. The units were sold in a registered direct offering under the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). The Company received total proceeds, net of offering expenses and placement agency fees, of $11.9 million. The proceeds will be used for general corporate purposes, including working capital, product development and capital expenditures, as well as for other strategic purposes.
"STEM in October announced new preclinical data showing that its human neural stem cells protect cone photoreceptors (cones) from progressive degeneration and preserve visual function long term. Cones are light sensing cells that are highly concentrated within the macula of the human eye, and the ability to protect these cells suggests a promising approach to treating age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55. These important findings were presented at the Society for Neuroscience 2009 Annual Meeting."
Read the entire report: http://www.investorsoup.com/lp/STEM
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.